Zobrazeno 1 - 10
of 56
pro vyhledávání: '"for the Swiss Group for Clinical Cancer Research SAKK"'
Autor:
Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and
Externí odkaz:
https://doaj.org/article/71614de5d82b474e855269ada1ea2dee
Autor:
Martin Fehr, Hanne Hawle, Stefanie Hayoz, Peter Thuss-Patience, Sabina Schacher, Jorge Riera Knorrenschild, Donat Dürr, Wolfram T. Knoefel, Holger Rumpold, Michael Bitzer, Martin Zweifel, Panagiotis Samaras, Ulrich Mey, Marc Küng, Ralph Winterhalder, Wolfgang Eisterer, Viviane Hess, Marie-Aline Gérard, Arnoud Templeton, Michael Stahl, Thomas Ruhstaller, for the Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), the Fédération Francophone de Cancérologie Digestive (FFCD) / Fédération de Recherche en Chirurgie (FRENCH)
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background High rates of venous thromboembolic events (VTEs), mainly in advanced disease, are reported for patients with cancer of the upper gastrointestinal tract (stomach, pancreas) and for treatment with cisplatin. Methods Exploratory ana
Externí odkaz:
https://doaj.org/article/0081a584ac4248f78e6831be4adafd73
Autor:
Cédric M. Panje, Laura Höng, Stefanie Hayoz, Vickie E. Baracos, Evelyn Herrmann, Helena Garcia Schüler, Urs R. Meier, Guido Henke, Sabina Schacher, Hanne Hawle, Marie-Aline Gérard, Thomas Ruhstaller, Ludwig Plasswilm, for the Swiss Group for Clinical Cancer Research (SAKK)
Publikováno v:
Radiation Oncology, Vol 14, Iss 1, Pp 1-7 (2019)
Abstract Background Sarcopenia, the critical depletion of skeletal muscle mass, is an independent prognostic factor in several tumor entities for treatment-related toxicity and survival. In esophageal cancer, there have been conflicting results regar
Externí odkaz:
https://doaj.org/article/a6c19732d9914c6da5052997e4c4898e
Autor:
Bernhard C. Pestalozzi, Christoph Tausch, Konstantin J. Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, Ralph Winterhalder, Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, Catrina Uhlmann Nussbaum, Bettina Seifert, Martin Bigler, Vincent Bize, Simona Berardi Vilei, Christoph Rageth, Stefan Aebi, The Swiss Group for Clinical Cancer Research (SAKK)
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). Methods SAKK 26/10 is a multicenter, prospective cohort study
Externí odkaz:
https://doaj.org/article/c9a8ea8a27db4f48921538bf341f9e66
Autor:
Joerger, Markus, Metaxas, Yannis, Zaman, Khalil, Michielin, Olivier, Mach, Nicolas, Bettini, Adrienne, Schmitt, Andreas M, Cantoni, Nathan, Caspar, Clemens B, Stettler, Sonja, Malval, Roma, Pless, Miklos, Britschgi, Christian, Renner, Christoph, Koeberle, Dieter, Schulz, Jessica D, Kopp, Christoph, Hayoz, Stefanie, Stathis, Anastasios, von Moos, Roger, Swiss Group for Clinical Cancer Research (SAKK)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3188a4fbfcaf16399e6c1ecb0c70822f
Autor:
F. Hitz, M. Kraus, T. Pabst, D. Hess, L. Besse, T. Silzle, U. Novak, K. Seipel, S. Rondeau, S. Stüdeli, S. Berardi Vilei, P. Samaras, U. Mey, C. Driessen, for the Swiss Group for Clinical Cancer Research SAKK
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 9, Pp 1-8 (2019)
Hitz, F; Kraus, M; Pabst, Thomas; Hess, D; Besse, L; Silzle, T; Novak, Urban; Seipel, Katja; Rondeau, S; Stüdeli, S; Vilei, S Berardi; Samaras, P; Mey, U; Driessen, C (2019). Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood cancer journal, 9(9), p. 70. Springer Nature 10.1038/s41408-019-0228-2
Blood Cancer Journal
Hitz, F; Kraus, M; Pabst, Thomas; Hess, D; Besse, L; Silzle, T; Novak, Urban; Seipel, Katja; Rondeau, S; Stüdeli, S; Vilei, S Berardi; Samaras, P; Mey, U; Driessen, C (2019). Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood cancer journal, 9(9), p. 70. Springer Nature 10.1038/s41408-019-0228-2
Blood Cancer Journal
The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding nelfinavir to lenalidomide–dexamethasone can overcome lenalidomide resistance in lenalidomide-r
Autor:
Rothschild, Sacha I., Zippelius, Alfred, Eboulet, Eric I., Savic Prince, Spasenija, Betticher, Daniel, Bettini, Adrienne, Früh, Martin, Joerger, Markus, Lardinois, Didier, Gelpke, Hans, Mauti, Laetitia A., Britschgi, Christian, Weder, Walter, Peters, Solange, Mark, Michael, Cathomas, Richard, Ochsenbein, Adrian F., Janthur, Wolf-Dieter, Waibel, Christine, Mach, Nicolas, Froesch, Patrizia, Buess, Martin, Bohanes, Pierre, Godar, Gilles, Rusterholz, Corinne, Gonzalez, Michel, Pless, Miklos, Swiss Group for Clinical Cancer Research (SAKK)
Publikováno v:
Journal of Clinical Oncology, Vol. 39, No 26 (2021) pp. 2872-2880
PURPOSE For patients with resectable stage IIIA(N2) non–small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% in the SAKK 16/00 trial and is an a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fcc38f12897a7adcc20a6ba5a660656
https://archive-ouverte.unige.ch/unige:155816
https://archive-ouverte.unige.ch/unige:155816
Autor:
Vees, Hansjörg, Caparrotti, Francesca, Eboulet, Eric Innocents, Xyrafas, Alexandros, Fuhrer, Andrea, Meier, Urs, Mark, Michael, Eliçin, Olgun, Aebersold, Daniel M., Zwahlen, Daniel R, Finazzi, Tobias, Allal, Abdelkarim Said, Putora, Paul Martin, Martucci, Francesco, Rudolf, Christine Biaggi, Ribi, Karin, Swiss Group For Clinical Cancer Research (SAKK), (SAKK)
PURPOSE To evaluate neurocognitive function (NCF) and clinical outcomes after early hippocampal avoidance (HA) prophylactic cranial irradiation (PCI) in limited disease (LD) small-cell lung cancer (SCLC). METHODS AND MATERIALS In a phase II trial, pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d69d9bc833a4776e68ca96386ad7e01
Autor:
Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J, Schouten, Harry C, Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E, de Weerdt, Okke, Legdeur, Marie-Cecile J C, Kuball, Juergen, Kooy, Marinus van Marwijk, Gjertsen, Bjorn T, Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A, van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A, Chalandon, Yves, Passweg, Jakob, Valk, Peter J M, Manz, Markus G, Ossenkoppele, Gert J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)
Publikováno v:
Löwenberg, B, Pabst, T, Maertens, J, Van Norden, Y, Biemond, B J, Schouten, H C, Spertini, O, Vellenga, E, Graux, C, Havelange, V, De Greef, G E, De Weerdt, O, Legdeur, M C J C, Kuball, J, Van Marwijk Kooy, M, Gjertsen, B T, Jongen-Lavrencic, M, Van De Loosdrecht, A A, Van Lammeren-Venema, D, Hodossy, B, Breems, D A, Chalandon, Y, Passweg, J, Valk, P J M, Manz, M G & Ossenkoppele, G J 2017, ' Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML ', Blood, vol. 129, no. 12, pp. 1636-1645 . https://doi.org/10.1182/blood-2016-10-740613
Blood, 129(12), 1636-1645. The American Society of Hematology
Blood, 129(12), 1636-1645. American Society of Hematology
Blood, 129(12), 1636-1645. AMER SOC HEMATOLOGY
Blood, Vol. 129, No 12 (2017) pp. 1636-1645
Blood, 129(12), 1636. American Society of Hematology
Blood, 129(12), 1636-1645. The American Society of Hematology
Blood, 129(12), 1636-1645. American Society of Hematology
Blood, 129(12), 1636-1645. AMER SOC HEMATOLOGY
Blood, Vol. 129, No 12 (2017) pp. 1636-1645
Blood, 129(12), 1636. American Society of Hematology
Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be critically evaluated in younger adults in the frontline with standard chemotherapy. We compared 2 induction regimens in newly diagnosed patients ages
Autor:
Riesterer, Oliver, Frank Ciernik, I, Stahel, Rolf A, Xyrafas, Alexandros, Aebersold, Daniel M, Plasswilm, Ludwig, Mahmut Ozsahin, E, Zwahlen, Daniel R, Nackaerts, Kristiaan, Zimmermann, Frank, Sabrina Stark, L, Weder, Walter, Krayenbuehl, Jérôme, Swiss Group for Clinical Cancer Research (SAKK)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______885::f9e4147a021ed890641a115bd6cd923c
https://doi.org/10.5167/uzh-175112
https://doi.org/10.5167/uzh-175112